Lomond Therapeutics Holdings, Inc. 8-K

What Happened
Lomond Therapeutics, Inc. (the “Company”) entered into a Termination Agreement with Bala Therapeutics, Inc. on January 7, 2026, under which the License Agreement dated October 17, 2024 was terminated ab initio and is effective immediately. The License covered certain intellectual property related to an early‑stage menin inhibitor for treating AML. The parties also terminated a Deferred Payment Agreement (a promissory note) under which the Company had agreed to pay Bala $1.2 million. The filing was made on January 13, 2026.

Key Details

• Termination effective January 7, 2026; License Agreement originally dated October 17, 2024.
• Company had spent approximately $600,000 on development of the Licensed IP under the License Agreement.
• Deferred Payment Agreement for $1.2 million (obligation to Bala) was terminated in connection with the termination of the License.
• As consideration for the Company’s expenditures and the termination, Bala agreed to issue shares to the Company equal to approximately 3.5% of Bala’s fully diluted capitalization as of the termination date.

Why It Matters
This filing ends Lomond’s exclusive rights to the licensed menin‑inhibitor program and removes a future payment obligation (the $1.2M deferred note). The Company receives equity in Bala (≈3.5% of fully diluted shares) and records that it had invested about $600k in the program. For investors, the item signals a strategic pullback from a development program the company judged to face a crowded, capital‑intensive competitive landscape and clarifies that those assets and obligations are no longer part of Lomond’s development roadmap.